| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0091270006286436 |
| P698 | PubMed publication ID | 16638733 |
| P2093 | author name string | Philip T Sager | |
| Borje Darpo | |||
| Thierry Nebout | |||
| P2860 | cites work | Drug induced QT prolongation and torsades de pointes | Q24673854 |
| Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride | Q33147807 | ||
| Terfenadine-associated ventricular arrhythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization | Q33173629 | ||
| Arrhythmogenic mechanisms of non-sedating antihistamines | Q33709818 | ||
| Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling | Q34289625 | ||
| The significance of QT interval in drug development | Q34808276 | ||
| Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval | Q35579763 | ||
| Assessment of drug-induced QT prolongation: to bin or not to bin? | Q36132399 | ||
| Inter- and intraday variability in major electrocardiogram intervals and amplitudes in healthy men and women | Q39646833 | ||
| Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. | Q39674138 | ||
| Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers | Q41830782 | ||
| The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. | Q42687064 | ||
| Problems of heart rate correction in assessment of drug-induced QT interval prolongation. | Q43594994 | ||
| Moxifloxacin does increase the corrected QT interval | Q43743491 | ||
| Modulation of QT interval during autonomic nervous system blockade in humans | Q44187491 | ||
| Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects | Q44351198 | ||
| Effects of three fluoroquinolones on QT interval in healthy adults after single doses | Q44413098 | ||
| Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. | Q44844508 | ||
| Clinical assessment of drug-induced QT prolongation in association with heart rate changes | Q46498375 | ||
| Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. | Q50885774 | ||
| QTc interval (cardiac repolarization): lengthening after meals. | Q51571943 | ||
| Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects | Q57314101 | ||
| Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability | Q71008927 | ||
| Cisapride and fatal arrhythmia | Q71133416 | ||
| The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada | Q73096129 | ||
| Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride | Q73222630 | ||
| Within-subject electrocardiographic differences at equal heart rates: role of the autonomic nervous system | Q73731988 | ||
| Drug-induced prolongation of the QT interval: why the regulatory concern? | Q74178435 | ||
| Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity | Q74178449 | ||
| Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction | Q78513477 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 498-507 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. | |
| P478 | volume | 46 |
| Q39871580 | A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. |
| Q80648171 | A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499 |
| Q35918516 | A k-nearest neighbor classification of hERG K(+) channel blockers |
| Q42194344 | A simple approach discriminating cardio-safe drugs from toxic ones |
| Q36275411 | A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer |
| Q51528930 | A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants. |
| Q43279508 | Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. |
| Q43260525 | Absence of effect of telbivudine on cardiac repolarization: results of a thorough QT/QTc study in healthy participants |
| Q38504869 | Additional safety risk to exceptionally approved drugs in Europe? |
| Q33785146 | Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study |
| Q39783830 | Analysis of the nonclinical telemetered ECG: impact of logging rate and RR bin width in the dog and cynomolgus monkey |
| Q33542747 | Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System |
| Q48596403 | Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin |
| Q89842622 | Are antibiotics substandard in Lebanon? Quantification of active pharmaceutical ingredients between brand and generics of selected antibiotics |
| Q33160123 | Assessing QT interval prolongation and its associated risks with antipsychotics. |
| Q51505796 | Assessing the probability of drug-induced QTc-interval prolongation during clinical drug development. |
| Q63363578 | Can laypeople identify a drug-induced QT interval prolongation? A psychophysical and eye-tracking experiment examining the ability of nonexperts to interpret an ECG |
| Q38098277 | Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia |
| Q112609285 | CardioTox net: a robust predictor for hERG channel blockade based on deep learning meta-feature ensembles |
| Q39002111 | Cardiovascular toxicities of systemic treatments of prostate cancer. |
| Q26745519 | Chronic obstructive pulmonary disease and sudden cardiac death: A systematic review |
| Q31128049 | Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping |
| Q33755778 | Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine |
| Q52628141 | Corrected QT interval prolongation during anesthetic induction for laryngeal mask airway insertion with or without cisatracurium. |
| Q62648884 | Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity |
| Q51899701 | Design of the "Thorough QT Study". |
| Q48106844 | Differential effects of propofol and sevoflurane on QT interval during anesthetic induction |
| Q33745061 | Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? |
| Q35016710 | Does the prulifloxacin ECG study prove cardiac safety of the drug? |
| Q37462061 | Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects |
| Q44069328 | Effect of Number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost |
| Q43442926 | Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization |
| Q41582221 | Effect of axitinib on the QT interval in healthy volunteers. |
| Q42268257 | Effect of intravenous zanamivir on cardiac repolarization |
| Q36558247 | Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects |
| Q35693620 | Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies |
| Q46619908 | Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers |
| Q55035299 | Evaluating cardiac risk: exposure response analysis in early clinical drug development. |
| Q30620268 | Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge |
| Q42872461 | Evaluation of terfenadine and ketoconazole-induced QT prolongation in conscious telemetered guinea pigs |
| Q44303636 | Evaluation of the cardiac toxicity of N-methyl-glucamine antimoniate in dogs with naturally occurring leishmaniasis |
| Q37156289 | Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period |
| Q37369309 | Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation |
| Q38679113 | Influence of Meals and Glycemic Changes on QT Interval Dynamics |
| Q40770030 | Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients |
| Q37184414 | Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes |
| Q42632466 | Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study |
| Q49990688 | Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor |
| Q38193042 | Myocardial tissue engineering: in vitro models |
| Q37353460 | Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions |
| Q37008418 | On the relationship among QT interval, atrial fibrillation, and torsade de pointes |
| Q38485341 | Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study |
| Q53222283 | Performance characteristics for some typical QT study designs under the ICH E-14 guidance. |
| Q39573728 | Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. |
| Q36120691 | Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia |
| Q33812750 | Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the 'bad' sodium current blockers |
| Q36801850 | Principles of safety pharmacology |
| Q31155117 | QT/QTc prolongation in placebo-treated subjects: a PhRMA collaborative data analysis |
| Q31129877 | Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG Warehouse |
| Q92525475 | Relationship of clinical adverse event reports to models of arrhythmia risk |
| Q50439761 | Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase |
| Q84599850 | Risperidone‐Induced QT Prolongation Following Overdose Correlates With Serum Drug Concentration and Resolves Rapidly With No Evidence of Altered Pharmacokinetics |
| Q46090429 | Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies |
| Q42327009 | Rupatadine: pharmacological profile and its use in the treatment of allergic rhinitis |
| Q37607325 | Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis |
| Q47848579 | Sex-related differences in the effect-site concentration of remifentanil for preventing QTc interval prolongation following intubation in elderly patients with a normal QTc interval. |
| Q35037346 | Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk |
| Q38174186 | The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?". |
| Q28482737 | The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blocker |
| Q47386135 | The effects of intravenous anesthetics on QT interval during anesthetic induction with sevoflurane. |
| Q48009913 | The interaction of antiemetic dose of droperidol with propofol on QT interval during anesthetic induction |
| Q26866417 | The role of concentration-effect relationships in the assessment of QTc interval prolongation |
| Q33661017 | The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance |
| Q35661122 | The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel |
| Q37650057 | Thorough QT Studies: Questions and Quandaries |
| Q45351775 | Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development. |
| Q38501976 | Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit |
| Q31042993 | Validation and utility of the PhysioTel™ Digital M11 telemetry implant for cardiovascular data evaluation in cynomolgus monkeys and Beagle dogs |
| Q37076140 | Which QT Correction Formulae to Use for QT Monitoring? |
Search more.